{"id":92779,"date":"2026-02-09T11:22:31","date_gmt":"2026-02-09T10:22:31","guid":{"rendered":"https:\/\/www.anderapartners.com\/?p=92779"},"modified":"2026-02-09T11:25:48","modified_gmt":"2026-02-09T10:25:48","slug":"agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo","status":"publish","type":"post","link":"https:\/\/www.anderapartners.com\/fr\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/","title":{"rendered":"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO"},"content":{"rendered":"<p class=\"elementToProof\">Andera Partners announced today that Agomab, one of its portfolio companies, has completed a $200 million initial public offering\u00a0on the NASDAQ stock market. The Company is trading under the ticker AGMB and it made its public market debut on February 6th.<\/p>\n<p class=\"elementToProof\">Funds raised from the offering will support clinical advancement\u00a0of ontunisertib, the company&rsquo;s lead clinical-stage candidate\u2014a GI-restricted ALK5 inhibitor in Phase 2 development for Fibrostenosing Crohn&rsquo;s Disease\u2014alongside AGMB-447, which is undergoing Phase 1 evaluation for Idiopathic Pulmonary Fibrosis.<\/p>\n<p>&nbsp;<\/p>\n<p class=\"elementToProof\"><b><i>Jan Van den Bossche, Partner at Andera Partners<\/i><\/b><i>, added: \u00ab\u00a0Agomab&rsquo;s journey from the Series A in 2019\u00a0to the remarkable Nasdaq IPO exemplifies the kind of <\/i><i>consistent value creation we seek to support at Andera Partners. Completing a $200 million IPO in the current volatile\u00a0capital markets environment is particularly remarkable for a European biotech. It is also a testament to the quality of both the science and the team behind it, benefiting from the strong Belgian biotech ecosystem. As an early investor in the company, we&rsquo;ve witnessed the caliber of this management team and their ability to execute on an ambitious clinical roadmap. The therapeutic programs they&rsquo;ve advanced hold genuine promise to transform treatment options for patients facing conditions with limited alternatives, and we&rsquo;re excited to\u00a0follow them in this next chapter.\u201d<\/i><\/p>\n<p class=\"elementToProof\">\n","protected":false},"excerpt":{"rendered":"<p>Andera Partners announced today that Agomab, one of its portfolio companies, has completed a $200 million initial public offering\u00a0on the NASDAQ stock market. The Company is trading under the ticker AGMB and it made its public market debut on February 6th. Funds raised from the offering will support clinical advancement\u00a0of ontunisertib, the company&rsquo;s lead clinical-stage&#8230;<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":[],"categories":[123],"class_list":["post-92779","post","type-post","status-publish","format-standard","hentry","category-biodiscovery-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO - ANDERA PARTNERS<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO - ANDERA PARTNERS\" \/>\n<meta property=\"og:description\" content=\"Andera Partners announced today that Agomab, one of its portfolio companies, has completed a $200 million initial public offering\u00a0on the NASDAQ stock market. The Company is trading under the ticker AGMB and it made its public market debut on February 6th. Funds raised from the offering will support clinical advancement\u00a0of ontunisertib, the company&rsquo;s lead clinical-stage...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/\" \/>\n<meta property=\"og:site_name\" content=\"ANDERA PARTNERS\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-09T10:22:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-09T10:25:48+00:00\" \/>\n<meta name=\"author\" content=\"Nicolas Delsert\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nicolas Delsert\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/\"},\"author\":{\"name\":\"Nicolas Delsert\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\"},\"headline\":\"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO\",\"datePublished\":\"2026-02-09T10:22:31+00:00\",\"dateModified\":\"2026-02-09T10:25:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/\"},\"wordCount\":230,\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"articleSection\":[\"andera Life Sciences\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/\",\"url\":\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/\",\"name\":\"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO - ANDERA PARTNERS\",\"isPartOf\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\"},\"datePublished\":\"2026-02-09T10:22:31+00:00\",\"dateModified\":\"2026-02-09T10:25:48+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.anderapartners.com\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#website\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"name\":\"ANDERA PARTNERS\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#organization\",\"name\":\"Andera Partners\",\"url\":\"https:\/\/www.anderapartners.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"contentUrl\":\"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg\",\"width\":107,\"height\":44,\"caption\":\"Andera Partners\"},\"image\":{\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c\",\"name\":\"Nicolas Delsert\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g\",\"caption\":\"Nicolas Delsert\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO - ANDERA PARTNERS","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/","og_locale":"fr_FR","og_type":"article","og_title":"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO - ANDERA PARTNERS","og_description":"Andera Partners announced today that Agomab, one of its portfolio companies, has completed a $200 million initial public offering\u00a0on the NASDAQ stock market. The Company is trading under the ticker AGMB and it made its public market debut on February 6th. Funds raised from the offering will support clinical advancement\u00a0of ontunisertib, the company&rsquo;s lead clinical-stage...","og_url":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/","og_site_name":"ANDERA PARTNERS","article_published_time":"2026-02-09T10:22:31+00:00","article_modified_time":"2026-02-09T10:25:48+00:00","author":"Nicolas Delsert","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"Nicolas Delsert","Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/#article","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/"},"author":{"name":"Nicolas Delsert","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c"},"headline":"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO","datePublished":"2026-02-09T10:22:31+00:00","dateModified":"2026-02-09T10:25:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/"},"wordCount":230,"publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"articleSection":["andera Life Sciences"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/","url":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/","name":"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO - ANDERA PARTNERS","isPartOf":{"@id":"https:\/\/www.anderapartners.com\/fr\/#website"},"datePublished":"2026-02-09T10:22:31+00:00","dateModified":"2026-02-09T10:25:48+00:00","breadcrumb":{"@id":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.anderapartners.com\/en\/agomab-portfolio-company-of-andera-partners-completes-successful-nasdaq-listing-with-200-million-ipo\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.anderapartners.com\/fr\/"},{"@type":"ListItem","position":2,"name":"Agomab, portfolio company of Andera Partners, completes successful Nasdaq listing with $200 million IPO"}]},{"@type":"WebSite","@id":"https:\/\/www.anderapartners.com\/fr\/#website","url":"https:\/\/www.anderapartners.com\/fr\/","name":"ANDERA PARTNERS","description":"","publisher":{"@id":"https:\/\/www.anderapartners.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.anderapartners.com\/fr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.anderapartners.com\/fr\/#organization","name":"Andera Partners","url":"https:\/\/www.anderapartners.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","contentUrl":"https:\/\/www.anderapartners.com\/wp-content\/uploads\/2020\/08\/logo-white.svg","width":107,"height":44,"caption":"Andera Partners"},"image":{"@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/dce1d4a32f2d85f191a44527e202942c","name":"Nicolas Delsert","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.anderapartners.com\/fr\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/fca7b29302058c85588bc6bc3db9bd1e?s=96&d=mm&r=g","caption":"Nicolas Delsert"}}]}},"_links":{"self":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/92779","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/comments?post=92779"}],"version-history":[{"count":2,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/92779\/revisions"}],"predecessor-version":[{"id":92781,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/posts\/92779\/revisions\/92781"}],"wp:attachment":[{"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/media?parent=92779"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.anderapartners.com\/fr\/wp-json\/wp\/v2\/categories?post=92779"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}